Investing in a trusted partner to the world’s leading diagnostic and healthcare organisations
Deal size, November 2015
BBI Group is a leading B2B manufacturer and services provider to in vitro diagnostic healthcare, food safety and military bio-threat detection companies globally. Its blue chip customer base includes Merck, Siemens, Thermo-Fisher and the US Department of Defense.
The company was acquired from Alere, a US publicly-quoted healthcare business. Exponent worked alongside our Operating Chairperson Alan Peterson to build the buy-out plan with BBI’s management team, led by Lyn Rees.
We were attracted to BBI by its market leading gold colloid formulation which is used in a wide range of diagnostic tests, as well as the opportunity to expand the product range and accelerate growth into new geographic markets.